Clinical features and therapeutic perspectives on hypertension in diabetics

[1]  T. Ohkubo,et al.  Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese , 2017, Hypertension Research.

[2]  T. Nakayama,et al.  Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report of Committee on Causes of Death in Diabetes Mellitus , 2017, Diabetology International.

[3]  T. Nakayama,et al.  Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus , 2017, Journal of diabetes investigation.

[4]  A. Nishiyama,et al.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure , 2017, Hypertension Research.

[5]  J. Fleg,et al.  Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance , 2016, Hypertension.

[6]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[7]  K. Kario,et al.  Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study , 2016, Hypertension Research.

[8]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[9]  M. Smolensky,et al.  Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks , 2016, Hypertension Research.

[10]  K. Wakai,et al.  An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013) , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[11]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[12]  Y. Matsuyama,et al.  The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes , 2015, BMJ Open Diabetes Research and Care.

[13]  Y. Kim,et al.  Morning hypertension and night non-dipping in patients with diabetes and chronic kidney disease , 2015, Hypertension Research.

[14]  A. Kashiwagi,et al.  Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study , 2015, Diabetology International.

[15]  A. Kiyosue,et al.  Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise , 2014, Diabetes, obesity & metabolism.

[16]  M. Woodward,et al.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.

[17]  I. Tikkanen,et al.  Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.

[18]  A. Sato,et al.  Diabetes and obesity are significant risk factors for morning hypertension : From Ibaraki Hypertension Assessment Trial ( I-HAT ) 著者 , 2017 .

[19]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[20]  Alan Bernjak,et al.  Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk , 2014, Diabetes.

[21]  Y. Seino,et al.  Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study , 2014, Current medical research and opinion.

[22]  Y. Terauchi,et al.  Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study , 2014, Cardiovascular Diabetology.

[23]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[24]  A. Kimura,et al.  Vital Signs, QT Prolongation, and Newly Diagnosed Cardiovascular Disease During Severe Hypoglycemia in Type 1 and Type 2 Diabetic Patients , 2013, Diabetes Care.

[25]  M. Roden,et al.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.

[26]  M. Woodward,et al.  Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus: The ADVANCE Trial , 2013, Circulation.

[27]  D. Matthews,et al.  Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes , 2013, Annals of Internal Medicine.

[28]  J. Staessen,et al.  Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes , 2013, Journal of hypertension.

[29]  A. Goto,et al.  Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis , 2013, BMJ.

[30]  E. O’Brien,et al.  Masked Hypertension in Diabetes Mellitus: Treatment Implications for Clinical Practice , 2013, Hypertension.

[31]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[32]  R. Testa,et al.  Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes , 2012, Diabetes.

[33]  M. Husain,et al.  GLP-1 receptor agonists: A clinical perspective on cardiovascular effects , 2012, Diabetes & vascular disease research.

[34]  Tetsuhiro Tanaka,et al.  The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors , 2011, Current opinion in nephrology and hypertension.

[35]  Y. Iwamoto,et al.  Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes , 2011, Journal of diabetes investigation.

[36]  H. Yamashita,et al.  Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS) , 2011, Diabetologia.

[37]  R. Hermida,et al.  Influence of Time of Day of Blood Pressure–Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes , 2011, Diabetes Care.

[38]  F. T. E. Group,et al.  Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS) , 2011, Diabetologia.

[39]  KamenovZdravko,et al.  Diabetic erectile dysfunction as a risk factor for diabetic neuropathy , 2010 .

[40]  T. Ogihara,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) , 2009, Hypertension Research.

[41]  Philip Chowienczyk,et al.  Dissociation of Aortic Pulse Wave Velocity With Risk Factors for Cardiovascular Disease Other Than Hypertension: A Systematic Review , 2009, Hypertension.

[42]  M. Woodward,et al.  Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes , 2009, Diabetes Care.

[43]  T. Uzu,et al.  Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker , 2009, Clinical and Experimental Nephrology.

[44]  J. Teresi,et al.  Ambulatory Blood Pressure Monitoring and All-Cause Mortality in Elderly People With Diabetes Mellitus , 2009, Hypertension.

[45]  A. Yamashina,et al.  The Relationships of Cardiovascular Disease Risk Factors to Flow-Mediated Dilatation in Japanese Subjects Free of Cardiovascular Disease , 2008, Hypertension Research.

[46]  R. Klein,et al.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.

[47]  H. Parving,et al.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.

[48]  Rury R Holman,et al.  Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.

[49]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[50]  Kazuomi Kario,et al.  Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. , 2008, American journal of hypertension.

[51]  C. Zoccali,et al.  Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension , 2008, Diabetes.

[52]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[53]  Tomoo Ikarashi,et al.  The Bedtime Administration of Doxazosin Controls Morning Hypertension and Albuminuria in Patients with Type-2 Diabetes: Evaluation Using Home-Based Blood Pressure Measurements , 2005, Clinical and experimental hypertension.

[54]  G. Reboldi,et al.  Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects , 2004, Hypertension.

[55]  K. Fushimi,et al.  An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001) 1 , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[56]  A. Yamashina,et al.  Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[57]  K. Kamoi,et al.  Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. , 2003, Diabetes care.

[58]  K. Kamoi,et al.  Usefulness of home blood pressure measurement in the morning in type 1 diabetic patients. , 2002, Diabetes care.

[59]  J. Redón,et al.  Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. , 2002, The New England journal of medicine.

[60]  R. Kawamori,et al.  Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. , 2002, Diabetes care.

[61]  E. Porteri,et al.  Structural Alterations in Subcutaneous Small Arteries of Normotensive and Hypertensive Patients With Non–Insulin-Dependent Diabetes Mellitus , 2001, Circulation.

[62]  W. Schady,et al.  Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial , 1998, The Lancet.

[63]  T. Kigoshi,et al.  Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. , 1998, Diabetes.

[64]  Shigeru Hisamichi,et al.  Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population‐based observation in Ohasama, Japan , 1998, Journal of hypertension.

[65]  H. Gerstein,et al.  The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. , 1997, Archives of internal medicine.

[66]  K. Forrest,et al.  Hypertension as a Risk Factor for Diabetic Neuropathy: A Prospective Study , 1997, Diabetes.

[67]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[68]  J. Strong,et al.  Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[69]  G. Jerums,et al.  Day-Night Blood Pressure Variation in Normotensive, Normoalbuminuric Type I Diabetic Subjects: Dippers and non-dippers , 1994, Diabetes Care.

[70]  V. Spallone,et al.  Relationship Between Autonomic Neuropathy, 24-h Blood Pressure Profile, and Nephropathy in Normotensive IDDM Patients , 1994, Diabetes Care.

[71]  J. Mallion,et al.  Early Disturbances of Ambulatory Blood Pressure Load in Normotensive Type I Diabetic Patients With Microalbuminuria , 1992, Diabetes Care.

[72]  T. Kamada,et al.  Prevalence of Carotid Atherosclerosis in Diabetic Patients Ultrasound high-resolution B-mode imaging on carotid arteries , 1992, Diabetes Care.

[73]  R. Gans,et al.  Acute hyperinsulinemia induces sodium retention and a blood pressure decline in diabetes mellitus. , 1992, Hypertension.

[74]  V. Salomaa,et al.  Glucose tolerance and blood pressure: long term follow up in middle aged men. , 1991, BMJ.

[75]  A. Itabashi,et al.  Effect of Captopril on Glucose Concentration: Possible Role of Augmented Postprandial Forearm Blood Flow , 1990, Diabetes Care.

[76]  C. Berne,et al.  A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. , 1989, The New England journal of medicine.

[77]  É. Alamartine,et al.  Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. , 1988 .

[78]  E. Ferrannini,et al.  Insulin resistance in essential hypertension. , 1987, The New England journal of medicine.

[79]  N. Christensen,et al.  Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in Type 1 (insulin-dependent) diabetes mellitus , 1987, Diabetologia.

[80]  D. Wilson,et al.  Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. , 1985, The New England journal of medicine.

[81]  J. Ditzel,et al.  Tubular Reabsorption Rates as Related to Elevated Glomerular Filtration in Diabetic Children , 1983, Diabetes.

[82]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[83]  K. Shimamoto.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 (JSH2014) , 2014 .

[84]  Yutaka Imai,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) , 2014, Hypertension Research.

[85]  K. Kario,et al.  Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study , 2014, Hypertension Research.

[86]  M. Litwin,et al.  Guidelines for the Management of Hypertension , 2015 .

[87]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[88]  H. Parving,et al.  DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. , 2008 .

[89]  T. Kigoshi,et al.  A prognostic role of mean 24-h pulse pressure level for cardiovascular events in type 2 diabetic subjects under 60 years of age. , 2005, Diabetes care.

[90]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[91]  T. Awata,et al.  Insulin levels during fasting and the glucose tolerance test and Homa's index predict subsequent development of hypertension , 2000, Journal of hypertension.

[92]  Endy,et al.  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults , 2000 .

[93]  R. Fogari,et al.  Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns. , 1993, American journal of hypertension.

[94]  M. Saad,et al.  Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[95]  K. Rett,et al.  Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. , 1988, The New England journal of medicine.

[96]  G GUIMARAES,et al.  Essential hypertension , 1950, Revue de medecine aeronautique.